30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
On February 26, 2020, Chancellor Andre G. Bouchard of the Delaware Court of Chancery denied a motion...
Read More >
The Legislature approved in first debate, by the unanimous vote of the 52 representatives present at...
Read More >
This morning the National Labor Relations Board (the “Board”) unveiled the final rule setting fort...
Read More >
No Good News, but No Bad News Either - On 16 October 2019 the European Commission (EC) adopted a de...
Read More >
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent deci...
Read More >
On January 21, 2020, the governor of New Jersey signed into law arguably the most stringent provisio...
Read More >